Which has higher earnings & valuation, NEO or LYFT?

Lyft has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Lyft, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.54 -$108.03M -$0.77 N/A Lyft $6.32B 0.86 $2.84B $6.85 2.08

Is NEO or LYFT more profitable?

Lyft has a net margin of 43.82% compared to NeoGenomics' net margin of -13.30%. Lyft's return on equity of -2.09% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Lyft 43.82% -2.09% -0.54%

Does the media favor NEO or LYFT?

In the previous week, Lyft had 19 more articles in the media than NeoGenomics. MarketBeat recorded 24 mentions for Lyft and 5 mentions for NeoGenomics. Lyft's average media sentiment score of 0.39 beat NeoGenomics' score of 0.38 indicating that Lyft is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyft 5 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor NEO or MARA?

In the previous week, Marathon Digital had 14 more articles in the media than NeoGenomics. MarketBeat recorded 19 mentions for Marathon Digital and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.38 beat Marathon Digital's score of 0.16 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marathon Digital 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, NEO or HNGE?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.54 -$108.03M -$0.77 N/A Hinge Health $587.86M 10.38 -$528.26M -$12.34 N/A

Is NEO or HNGE more profitable?

NeoGenomics has a net margin of -13.30% compared to Hinge Health's net margin of -78.95%. NeoGenomics' return on equity of -2.80% beat Hinge Health's return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Hinge Health -78.95% -310.62% -71.08%

Does the media refer more to NEO or HNGE?

In the previous week, Hinge Health had 18 more articles in the media than NeoGenomics. MarketBeat recorded 23 mentions for Hinge Health and 5 mentions for NeoGenomics. Hinge Health's average media sentiment score of 0.38 beat NeoGenomics' score of 0.38 indicating that Hinge Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hinge Health 11 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, AMTM or NEO?

Amentum has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Amentum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amentum $14.39B 0.34 $66M $0.60 33.75 NeoGenomics $727.33M 2.54 -$108.03M -$0.77 N/A

Is AMTM or NEO more profitable?

Amentum has a net margin of 1.04% compared to NeoGenomics' net margin of -13.30%. Amentum's return on equity of 11.74% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets Amentum 1.04% 11.74% 4.78% NeoGenomics -13.30% -2.80% -1.72%

Does the media prefer AMTM or NEO?

In the previous week, NeoGenomics had 3 more articles in the media than Amentum. MarketBeat recorded 5 mentions for NeoGenomics and 2 mentions for Amentum. NeoGenomics' average media sentiment score of 0.38 beat Amentum's score of 0.35 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amentum 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, NEO or SEZL?

Sezzle has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Sezzle, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.54 -$108.03M -$0.77 N/A Sezzle $450.28M 12.74 $133.13M $4.21 40.51

Is NEO or SEZL more profitable?

Sezzle has a net margin of 30.83% compared to NeoGenomics' net margin of -13.30%. Sezzle's return on equity of 87.46% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Sezzle 30.83% 87.46% 36.29%

Does the media favor NEO or SEZL?

In the previous week, Sezzle had 8 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Sezzle and 5 mentions for NeoGenomics. Sezzle's average media sentiment score of 0.78 beat NeoGenomics' score of 0.38 indicating that Sezzle is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sezzle 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeoGenomics (NEO) Competitors

$14.17 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$14.07 -0.10 (-0.71%)

As of 04:16 AM Eastern

Compare

NEO vs. LYFT, MARA, HNGE, AMTM, and SEZL

Should you buy NeoGenomics stock or one of its competitors? MarketBeat compares NeoGenomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeoGenomics include Lyft (LYFT), Marathon Digital (MARA), Hinge Health (HNGE), Amentum (AMTM), and Sezzle (SEZL). These companies are all part of the "business services" industry.

How does NeoGenomics compare to Lyft?

NeoGenomics (NASDAQ:NEO) and Lyft (NASDAQ:LYFT) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Lyft has a net margin of 43.82% compared to NeoGenomics' net margin of -13.30%. Lyft's return on equity of -2.09% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Lyft	43.82%	-2.09%	-0.54%

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 83.1% of Lyft shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 0.9% of Lyft shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lyft has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Lyft, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.54	-$108.03M	-$0.77	N/A
Lyft	$6.32B	0.86	$2.84B	$6.85	2.08

NeoGenomics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Lyft has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

In the previous week, Lyft had 19 more articles in the media than NeoGenomics. MarketBeat recorded 24 mentions for Lyft and 5 mentions for NeoGenomics. Lyft's average media sentiment score of 0.39 beat NeoGenomics' score of 0.38 indicating that Lyft is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyft	5 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

NeoGenomics presently has a consensus target price of $13.86, suggesting a potential downside of 2.21%. Lyft has a consensus target price of $19.40, suggesting a potential upside of 35.95%. Given Lyft's higher probable upside, analysts plainly believe Lyft is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Lyft	3 Sell rating(s)	21 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Lyft beats NeoGenomics on 11 of the 15 factors compared between the two stocks.

How does NeoGenomics compare to Marathon Digital?

NeoGenomics (NASDAQ:NEO) and Marathon Digital (NASDAQ:MARA) are both business services companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

NeoGenomics currently has a consensus target price of $13.86, indicating a potential downside of 2.21%. Marathon Digital has a consensus target price of $19.00, indicating a potential upside of 30.78%. Given Marathon Digital's stronger consensus rating and higher probable upside, analysts plainly believe Marathon Digital is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Marathon Digital	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

NeoGenomics has higher earnings, but lower revenue than Marathon Digital. NeoGenomics is trading at a lower price-to-earnings ratio than Marathon Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.54	-$108.03M	-$0.77	N/A
Marathon Digital	$907.09M	6.11	-$1.31B	-$5.72	N/A

In the previous week, Marathon Digital had 14 more articles in the media than NeoGenomics. MarketBeat recorded 19 mentions for Marathon Digital and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.38 beat Marathon Digital's score of 0.16 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marathon Digital	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 44.5% of Marathon Digital shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 1.0% of Marathon Digital shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeoGenomics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Marathon Digital has a beta of 5.38, indicating that its share price is 438% more volatile than the broader market.

NeoGenomics has a net margin of -13.30% compared to Marathon Digital's net margin of -234.83%. NeoGenomics' return on equity of -2.80% beat Marathon Digital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Marathon Digital	-234.83%	-23.20%	-12.51%

Summary

NeoGenomics and Marathon Digital tied by winning 8 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Hinge Health had 18 more articles in the media than NeoGenomics. MarketBeat recorded 23 mentions for Hinge Health and 5 mentions for NeoGenomics. Hinge Health's average media sentiment score of 0.38 beat NeoGenomics' score of 0.38 indicating that Hinge Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hinge Health	11 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.54	-$108.03M	-$0.77	N/A
Hinge Health	$587.86M	10.38	-$528.26M	-$12.34	N/A

NeoGenomics has a net margin of -13.30% compared to Hinge Health's net margin of -78.95%. NeoGenomics' return on equity of -2.80% beat Hinge Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Hinge Health	-78.95%	-310.62%	-71.08%

NeoGenomics presently has a consensus price target of $13.86, indicating a potential downside of 2.21%. Hinge Health has a consensus price target of $75.80, indicating a potential downside of 3.85%. Given NeoGenomics' higher probable upside, research analysts clearly believe NeoGenomics is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

NeoGenomics and Hinge Health tied by winning 8 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Amentum?

Amentum (NYSE:AMTM) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Amentum has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

Amentum presently has a consensus target price of $32.00, indicating a potential upside of 58.03%. NeoGenomics has a consensus target price of $13.86, indicating a potential downside of 2.21%. Given Amentum's higher possible upside, equities research analysts plainly believe Amentum is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amentum	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Amentum has a net margin of 1.04% compared to NeoGenomics' net margin of -13.30%. Amentum's return on equity of 11.74% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amentum	1.04%	11.74%	4.78%
NeoGenomics	-13.30%	-2.80%	-1.72%

39.9% of Amentum shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 19.4% of Amentum shares are owned by company insiders. Comparatively, 1.1% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amentum has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Amentum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amentum	$14.39B	0.34	$66M	$0.60	33.75
NeoGenomics	$727.33M	2.54	-$108.03M	-$0.77	N/A

In the previous week, NeoGenomics had 3 more articles in the media than Amentum. MarketBeat recorded 5 mentions for NeoGenomics and 2 mentions for Amentum. NeoGenomics' average media sentiment score of 0.38 beat Amentum's score of 0.35 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amentum	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amentum beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

How does NeoGenomics compare to Sezzle?

NeoGenomics (NASDAQ:NEO) and Sezzle (NASDAQ:SEZL) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

NeoGenomics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Sezzle has a beta of 6.96, meaning that its share price is 596% more volatile than the broader market.

Sezzle has a net margin of 30.83% compared to NeoGenomics' net margin of -13.30%. Sezzle's return on equity of 87.46% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Sezzle	30.83%	87.46%	36.29%

Sezzle has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Sezzle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.54	-$108.03M	-$0.77	N/A
Sezzle	$450.28M	12.74	$133.13M	$4.21	40.51

NeoGenomics currently has a consensus price target of $13.86, indicating a potential downside of 2.21%. Sezzle has a consensus price target of $136.00, indicating a potential downside of 20.26%. Given NeoGenomics' higher possible upside, research analysts clearly believe NeoGenomics is more favorable than Sezzle.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Sezzle	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 2.0% of Sezzle shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 49.5% of Sezzle shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sezzle had 8 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Sezzle and 5 mentions for NeoGenomics. Sezzle's average media sentiment score of 0.78 beat NeoGenomics' score of 0.38 indicating that Sezzle is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sezzle	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sezzle beats NeoGenomics on 13 of the 17 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-18.40	21.75	25.89	24.17
Price / Sales	2.54	334.18	546.41	101.77
Price / Cash	42.29	62.10	29.09	36.93
Price / Book	2.19	8.31	10.79	6.38
Net Income	-$108.03M	$23.92M	$3.58B	$337.00M
7 Day Performance	26.52%	1.93%	1.97%	-0.20%
1 Month Performance	34.70%	-0.41%	-0.24%	-1.40%
1 Year Performance	97.35%	65.22%	34.40%	27.76%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	1.3732 of 5 stars	$14.17 flat	$13.86 -2.2%	+97.4%	$1.85B	$727.33M	N/A	2,500	Analyst Upgrade Gap Down High Trading Volume
LYFT Lyft	4.7268 of 5 stars	$14.22 -0.4%	$18.93 +33.1%	-9.2%	$5.42B	$6.32B	2.08	3,913	Trending News Options Volume
MARA Marathon Digital	2.9088 of 5 stars	$14.85 +4.4%	$18.38 +23.7%	-3.3%	$5.42B	$867.82M	N/A	9	Options Volume Gap Down
HNGE Hinge Health	2.4696 of 5 stars	$68.59 -1.2%	$75.13 +9.5%	+70.1%	$5.37B	$646.34M	N/A	1,437	Gap Down
AMTM Amentum	4.5909 of 5 stars	$21.01 -3.0%	$32.00 +52.3%	-13.7%	$5.29B	$14.39B	35.01	50,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors